18f-dtbz    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
6Parkinson disease6

6. Parkinson disease    [ 2,123 clinical trials,   2,046 drugs,   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways]
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
6 / 2,123 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02059733
(ClinicalTrials.gov)
February 20137/2/2014Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and ParkinsonismDeveloping a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and Parkinsonism by 18F-DTBZ PETParkinson's DiseaseDrug: 18F-DTBZChang Gung Memorial HospitalNULLCompleted20 Years80 YearsAll72Phase 2Taiwan
2NCT02039024
(ClinicalTrials.gov)
March 201215/1/2014Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PETImaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PETParkinson's DiseaseDrug: 18F- DTBZChang Gung Memorial HospitalNational Science Council, TaiwanCompleted20 Years80 YearsBoth18Phase 2Taiwan
3NCT01556100
(ClinicalTrials.gov)
November 20116/3/2012Long-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease ProgressionLong-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease ProgressionParkinson DiseaseDrug: 18F-DTBZ AV-133Chang Gung Memorial HospitalNULLCompleted20 YearsN/AAll40Phase 2NULL
4NCT01759888
(ClinicalTrials.gov)
August 20111/1/2013Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 ParkinsonismFrom Mouse Models to Patients: Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 ParkinsonismParkinson's DiseaseDrug: 18F-DTBZChang Gung Memorial HospitalNational Science Council, TaiwanCompleted20 Years80 YearsBoth49Phase 2Taiwan
5NCT01824056
(ClinicalTrials.gov)
August 201012/3/2013The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission TomographyThe Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography With Vesicular Monoamine Transporter Ligand (18F-DTBZ)Parkinson's DiseaseDrug: 18F-FDGChang Gung Memorial HospitalNational Science Council, TaiwanCompleted20 Years80 YearsBoth120Phase 2Taiwan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01283347
(ClinicalTrials.gov)
May 201011/1/201118F-DTBZ for l Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET ImagingPhase II Study of 18F-DTBZ: The Differential Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET ImagingParkinson's DiseaseDrug: 18F-DTBZChang Gung Memorial HospitalNULLCompleted50 Years80 YearsBoth100Phase 2Taiwan